Skip to main content

Table 2 PRAGMA-CF CT scores at baseline and over two years of treatment with LUM/IVA.

From: The clinical impact of Lumacaftor-Ivacaftor on structural lung disease and lung function in children aged 6–11 with cystic fibrosis in a real-world setting

 

Baseline Mean (95% CI)

n = 32

Year 1 Mean (95% CI)

n = 32

Year 2 Mean (95% CI)

n = 31

p-value

%Bronchiectasis

0.82

(0.48–1.16)

0.85

(0.51–1.19)

1.24

(0.89–1.60)

0.005*

%Disease

2.78

(2.12–3.45)

2.46

(1.79–3.14)

2.25

(1.55–2.94)

0.138

%Trapped Air

13.88

(9.34–16.42)

10.12

(6.52–13.71)

7.09

(3.29–10.89)

0.016*

%Mucous plugging

0.57

(0.31–0.83)

0.28

(0.01–0.54)

0.33

(0.04–0.62)

0.221

  1. *p-values < 0.05. The p-value is for the trend over time (fixed effect of time) from the random coefficients model
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us